Abbisko Cayman Limited (2256.HK)
2256.HK Stock Price Chart
Explore Abbisko Cayman Limited interactive price chart. Choose custom timeframes to analyze 2256.HK price movements and trends.
2256.HK Company Profile
Discover essential business fundamentals and corporate details for Abbisko Cayman Limited (2256.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Oct 2021
Employees
281.00
Website
https://www.abbisko.comCEO
Yao-Chang Xu
Description
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company's primary product candidates are ABSK011, a small molecule inhibitor of fibroblast growth factor receptor 4 for the treatment of advanced hepatocellular carcinoma with hyper-activation of FGF19/FGFR4 signaling; and ABSK091, a molecularly targeted product candidate for the treatment of multiple solid tumors, including urothelial cancer, gastric cancer, cholangiocarcinoma, and lung cancer. It also has other pipeline product candidates. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
2256.HK Financial Timeline
Browse a chronological timeline of Abbisko Cayman Limited corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 4 Aug 2025
EPS came in at $0.56 matching the estimated $0.56, while revenue for the quarter reached $670.76M , meeting expectations.
Earnings released on 18 Jun 2025
Earnings released on 2 Mar 2025
EPS came in at -$0.16 surpassing the estimated -$0.42 by +62.16%, while revenue for the quarter reached $3.72M .
Earnings released on 31 Dec 2024
EPS came in at -$0.15 , while revenue for the quarter reached $3.57M .
Earnings released on 12 Aug 2024
EPS came in at $0.17 surpassing the estimated -$0.37 by +146.03%, while revenue for the quarter reached $267.01M , missing expectations by -50.00%.
Earnings released on 18 Jun 2024
EPS came in at $0.17 , while revenue for the quarter reached $269.00M .
Earnings released on 13 Mar 2024
EPS came in at -$0.18 surpassing the estimated -$0.57 by +67.69%.
Earnings released on 31 Dec 2023
EPS came in at -$0.19 .
Earnings released on 16 Aug 2023
EPS came in at -$0.18 surpassing the estimated -$0.59 by +69.06%, while revenue for the quarter reached $10.88M .
Earnings released on 30 Jun 2023
EPS came in at -$0.17 , while revenue for the quarter reached $10.31M .
Earnings released on 15 Mar 2023
EPS came in at -$0.28 surpassing the estimated -$0.49 by +42.68%.
Earnings released on 31 Dec 2022
EPS came in at -$0.29 .
Earnings released on 22 Aug 2022
EPS came in at -$0.19 falling short of the estimated -$0.17 by -14.43%, while revenue for the quarter reached $13.70M .
Earnings released on 30 Jun 2022
EPS came in at -$0.18 .
Earnings released on 18 Mar 2022
EPS came in at -$2.37 falling short of the estimated -$0.15 by -1.48K%, while revenue for the quarter reached $13.89M .
Earnings released on 14 Nov 2021
EPS came in at -$2.33 , while revenue for the quarter reached $13.68M .
Earnings released on 30 Sept 2021
EPS came in at -$0.42 .
Earnings released on 31 Mar 2021
EPS came in at -$0.21 .
2256.HK Stock Performance
Access detailed 2256.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.